相关临床试验
0
0 进行中
药物批准
0
批准总数
监管机构
0
监管机构数
成立时间
N/A
暂无试验阶段数据
暂无试验数据
暂无试验数据
暂无批准数据
- Taro Pharmaceutical Industries, a wholly-owned subsidiary of Sun Pharma, initiated a Class II nationwide recall of 17,664 units of Ciclopirox Shampoo on December 9, 2024. - The antifungal medication used to treat seborrheic dermatitis was recalled due to failed impurity and degradation specifications identified during manufacturing quality control. - The USFDA classified this as a Class II recall, indicating potential for temporary or medically reversible health consequences with minimal likelihood of serious adverse outcomes. - This recall highlights ongoing quality control challenges for Indian pharmaceutical companies, which supply four out of ten prescriptions filled in the US market.
- The US FDA issued eight observations to Sun Pharma's Halol manufacturing facility in Gujarat following a Good Manufacturing Practices inspection conducted from June 2-13, 2025. - The facility has been under an import alert since May 2022 and remains classified as OAI (Official Action Indicated) since March 2020, restricting exports to the US market. - Despite the regulatory challenges, UBS maintains a buy rating with a target price of Rs 2,450, while Nomura expects limited impact from potential site resolution given the company's large revenue base. - Sun Pharma announced a leadership transition with Kirti Ganorkar becoming Managing Director effective September 1, 2025, while founder Dilip Shanghvi will continue as Executive Chairman.
- Lupin has begun rolling out the first generic version of the blockbuster anticoagulant Xarelto (rivaroxaban) in the US market after the Patent Trial and Appeal Board invalidated a key patent. - The FDA has approved generic Xarelto applications from both Lupin and Sun Pharma's Taro subsidiary, marking significant competition for the J&J/Bayer blockbuster that generates billions in annual revenue. - Despite the launch, both generic manufacturers remain entangled in litigation with J&J/Bayer over a patent that doesn't expire until 2039, creating uncertainty about potential damages if the patent is ultimately upheld.
